RxDoctor Payments Data

Opeyemi Bello, NP

Psychiatric/Mental Health · Riverside, CANPI 1023497351

Payments from drug & device makers

$794in general payments, 2019–2025

Across 27 payments — averaging $29.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$171
  • Otsuka America Pharmaceutical, Inc.$143
  • Lundbeck LLC$127
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$100
  • E.r. Squibb & Sons, L.L.C.$55
  • Johnson & Johnson$54
  • plus $144 from 5 others

What the payments were for

  • Food & beverage$794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794 in reported general payments places this provider in the 65th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$13,359
Medicare patients
33
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate18$58,200
RexultiBrexpiprazole11$15,693
Lurasidone Hcl12$8,975
Aripiprazole19$2,462
Quetiapine Fumarate ErQuetiapine Fumarate17$1,609
Divalproex Sodium ErDivalproex Sodium30$1,010
Olanzapine52$852
Quetiapine Fumarate50$818
Bupropion XlBupropion Hcl43$778
Hydroxyzine Hcl23$587
Benztropine Mesylate53$536
Fluoxetine Hcl20$409
Haloperidol11$372
Prazosin Hcl13$310
Trazodone Hcl52$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$54$58,20018 claims
Otsuka America Pharmaceutical, Inc.Rexulti$143$15,69311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →